Tadarise is a tadalafil-branded product family in the portfolio published by Sunrise Remedies, an India-based pharmaceutical company. The company lists ordinary Tadarise tadalafil tablets in several strengths and separately advertises oral-jelly and effervescent products. Crucially, the similar-looking names Super Tadarise, Top Tadarise and Extra Super Tadarise are not simply strength options: the company identifies them as tadalafil plus dapoxetine combinations.
These corporate listings provide product-level detail that should not be reduced to generic statements about Indian ED brands. They do not establish independent quality testing for every lot or FDA authorization for the U.S. market. Some marketed strengths extend beyond the U.S. Cialis ED tablet presentations, so the numbers belong in brand identification, not patient self-dosing instructions.
This page focuses on Sunrise’s named products and differences in their declared compositions. Compare other foreign names in the Indian tadalafil directory; consult the U.S. generic guide for FDA-approved equivalents. Import advertisements and a company’s business-enquiry options should not be confused with lawful U.S. prescription fulfillment.
Sunrise Remedies identifies Tadarise in its ED and premature-ejaculation product category and describes the basic line as tadalafil tablets. The company also identifies itself as a pharmaceutical manufacturer; this supports a company-linked product relationship, without authenticating stock offered elsewhere.
The company site is a product-marketing source and includes commercial efficacy language. Editorial content should use its composition and product-name fields conservatively rather than repeating claims of guaranteed sexual performance or cure.
The normal Tadarise entry lists 2.5, 5, 10, 20, 40 and 60 mg tadalafil claims. Company pages separately describe some products with different dosage forms and combination ingredients. The strength on a marketing page is not an instruction to take the product or evidence of a U.S.-approved formulation.
The table shows the distinction that matters most to the reader: a tadalafil-only branded record versus a product containing another active drug.
| Product name | Company-listed composition or form | Classification |
|---|---|---|
| Tadarise tablets | Tadalafil strengths 2.5/5/10/20/40/60 mg | Single-ingredient marketed line |
| Tadarise Oral Jelly | Tadalafil 20 mg oral jelly claim | Separate form; not an approved U.S. tablet |
| Tadarise Effervescent | Tadalafil 20 mg effervescent claim | Separate form |
| Super Tadarise | Tadalafil 20 mg + dapoxetine 60 mg | Combination product |
| Top Tadarise | Tadalafil 20 mg + dapoxetine 30 mg | Combination product |
| Extra Super Tadarise | Tadalafil 40 mg + dapoxetine 60 mg | Combination product |
Sunrise’s Super Tadarise listing includes dapoxetine along with tadalafil. Dapoxetine is a different active ingredient associated with premature-ejaculation product claims. A combination changes the potential for adverse effects and interactions, and must never be described as interchangeable with a single-ingredient tadalafil tablet.
No U.S. approval or safety conclusion follows from a company’s combined-product advertisement. The corresponding prescribing framework for FDA-approved U.S. tadalafil does not cover an imported tadalafil–dapoxetine combination as if it were ordinary Cialis.
Top Tadarise is documented as tadalafil with a lower stated dapoxetine amount than Super Tadarise, while Extra Super Tadarise lists a larger tadalafil strength. These are separate named product claims, not synonyms or routine adjustment steps.
When websites shorten any of these labels to “Tadarise,” a reader may lose the second ingredient. Preserve the full trade name and exact composition in any editorial comparison and do not treat the products as a generic strength ladder.
Sunrise also markets Tadarise-branded oral-jelly and effervescent presentations. Those listings identify alternative dosage forms, but a U.S. patient should not infer that onset, absorption, bioequivalence or dispensing authorization matches a standard FDA-approved tadalafil tablet.
For a U.S. pharmacy prescription, the product and dosage form must match an approved and lawfully dispensed preparation. The branded foreign-market form alone is not evidence of therapeutic equivalence.
The Tadarise company catalog lists higher tablet strengths that lie outside the typical U.S. Cialis ED tablet presentations of 2.5, 5, 10 and 20 mg. Those figures may help recognize a product claim but should not be translated into better efficacy or a recommended regimen.
If the reader wants the American clinical framework, the U.S. tadalafil strengths guide explains the approved ED product families; this page remains about foreign brand identities.
Sunrise describes itself as the manufacturer on the product pages and offers business enquiries rather than direct retail checkout. Those are specific company-published assertions. Independent authentication of a particular package, distribution chain or manufacturing lot is still a separate question.
Copying a reseller’s broader inventory as current company output would weaken the evidence. Use the full Sunrise name, the actual product page and the ingredient field as the basis for a narrowly phrased claim.
A foreign product record does not substitute for the FDA’s approval and therapeutic-equivalence framework. U.S. ED prescriptions use appropriate FDA-approved branded or generic tadalafil products. Combination presentations advertised under Tadarise-related names do not inherit that status.
The Cialis brand overview and generic tadalafil page describe that separate U.S. product category without suggesting routine importation.
Tadalafil has serious contraindications with organic nitrates and riociguat. A Tadarise combination containing dapoxetine introduces additional drug-specific concerns not adequately addressed by simply repeating the tadalafil label. Without verified ingredients, neither a seller nor an article can determine appropriate therapy.
See tadalafil drug interactions for the ingredient framework. Do not combine foreign products, adjust strengths or rely on a company advertisement for personalized medical advice.
Sunrise’s marketing pages and reseller shipment claims do not establish FDA authorization or a routine lawful U.S. supply channel. The product names are included for research into branding and composition, not as recommended items for importing or purchasing.
If a clinician finds tadalafil appropriate, the U.S. pharmacy guide explains valid prescriptions and licensed dispensing. No live price, stock availability or foreign ordering recommendation is given here.
Tadarise is a Sunrise Remedies India-market product family with company-listed tadalafil tablet presentations.
No. Sunrise lists Super Tadarise as tadalafil plus dapoxetine, not tadalafil alone.
Sunrise product information lists tadalafil 20 mg and dapoxetine 30 mg for Top Tadarise.
Yes. The company lists tadalafil 40 mg plus dapoxetine 60 mg; it is a distinct combination product.
No. They are separately marketed dosage forms and should not be assumed FDA-approved or interchangeable.
No. Foreign marketed strengths are not an extension of the U.S. Cialis ED label.
Sunrise Remedies identifies itself as manufacturer in company product listings; the exact package and supply chain still require verification.
Do not assume so. FDA-approved U.S. tadalafil products require their own regulatory and dispensing records.